Clinical trial · no report yet · Phase 2
TUXEDO-1
Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases
- NCT04752059 ↗
- Completed
- Medical University of Vienna
- 30 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 12 | |
| YouTube | 11 | |
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer Stage IV
- Interventions
- Trastuzumab deruxtecan
- Arms
- T-DXd 5.4 mg · Experimental
- Enrollment
- 15
- Primary outcomes
- Reponse rate of brain metastases to trastuzumab-deruxtecan
- Sponsor
- Medical University of Vienna with Daiichi Sankyo
- Start
- Jul 28, 2020
- Primary completion
- May 1, 2023
- Results posted
- No
- Registry record
- NCT04752059 · updated May 12, 2023
Publications
linked from the registry- Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8. PubMed 35941372